Integrin targeted therapeutics.

Integrin targeted therapeutics.
复制标题

DOI:
10.7150/thno/v01p0154
复制
发表时间:
2011-02-17
期刊:
影响因子:
12.4
通讯作者:
Neamati N
Neamati N
中科院分区:
医学1区
文献类型:
--
作者:
Millard M;Odde S;Neamati N

文献摘要

参考文献

被引文献

相似文献

整合素是异源二聚体的跨膜受体,在许多生物过程中充当机械传感器、粘附分子和信号转导平台。因此,整联蛋白是许多疾病状态的病因学和病理学的核心。因此,整联蛋白的药理学抑制对于疾病的治疗和预防具有极大的意义。在过去的二十年中,几种整合素靶向药物已进入临床使用,许多其他药物正在临床试验中,随着它们通过临床前开发的进展,还有更多的药物显示出希望。在此,本文审查和评估的各种药物和化合物靶向整合素和疾病的状态,他们牵连。
Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated.
DOI: 10.1126/science.272.5258.60
发表时间: 1996-04-05
期刊: SCIENCE
影响因子: 56.9
作者:
Butcher, EC;Picker, LJ
通讯作者: Picker, LJ
DOI: 10.1172/jci10817
发表时间: 2001-06-01
影响因子: 15.9
作者:
Brittain, JE;Mlinar, KJ;Parise, LV
通讯作者: Parise, LV
DOI: 10.1182/blood.v100.6.2071.h81802002071_2071_2076
发表时间: 2002-09-15
期刊: BLOOD
影响因子: 20.3
作者:
Bougie, DW;Wilker, PR;Aster, RH
通讯作者: Aster, RH
DOI: 10.1172/jci118227
发表时间: 1995-10-01
影响因子: 15.9
作者:
BROOKS, PC;STROMBLAD, S;CHERESH, DA
通讯作者: CHERESH, DA